FDA Approves Large Studies of Ecstasy to Treat PTSD
Large-scale Phase 3 clinical trials of the illegal party drug Ecstasy as a treatment for post-traumatic stress disorder (PTSD) were approved Tuesday by the U.S. Food and Drug Administration.
Some small studies have yielded promising results. If the new trials are successful, Ecstasy (MDMA) could be approved as a prescription drug for PTSD, The New York Times reported.
An FDA spokeswoman declined to comment on the matter, citing rules that forbid providing information about drugs under development.
Click here to Read the full article: FDA Approves Large Studies of Ecstasy to Treat PTSD
Share this entry
- Jaimie Krzynski, BSN/RN, is Appointed to the American Health Council’s Board of Nurses July 20, 2017
- American Health Council Names Diana Getsy-Holiday, RN, CD, CAP, ChT, BHT, ICADC to Nursing Board July 20, 2017
- The American Health Council Names Paul Aoun, DO/PhD, to Board of Physicians July 19, 2017
- The AHC Names Ferdinando Mirarchi, DO/FAAEM/FACEP, to its Board of Physicians July 18, 2017
- American Health Council Appoints Jonel Kinser, BSN/RN, to its Board of Nurses July 18, 2017
- American Health Council Names Husam Issa, MD, With Admission to Physician Board July 17, 2017